340B is a federal program, started in 1992, that makes drugmakers sell outpatient medicines at steep discounts to hospitals and clinics that serve many low-income or uninsured patients.1AMCP.org. 340B Drug Pricing Program The discount goes to the provider, not to the patient at the pharmacy counter. What providers do with the savings is largely up to them, which is why the program draws both strong support and sharp criticism.
Who Qualifies for 340B Discounts
Congress required drugmakers that take part in Medicaid to offer the discounts.1AMCP.org. 340B Drug Pricing Program The stated goal was to let providers stretch scarce federal resources to reach more patients or offer more services.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments The program is run by HRSA, an agency of the Department of Health and Human Services.1AMCP.org. 340B Drug Pricing Program It began narrowly, aimed at federally funded clinics and public hospitals.3PubMed Central. Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program
Over the years the program has expanded substantially through law changes and broader readings of who counts as eligible.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments4PubMed Central. The unintended consequences of the 340B safety-net drug discount program. Hospitals gained wider access under the 2010 health care reform law.5PubMed Central. Health Care Reform Bill Expands Access to Section 340B Discounted Drugs for Hospitals.
Community health centers that get federal grants are classic participants. Nonprofit or public hospitals serving many low-income patients qualify, including some large systems, and rural Critical Access Hospitals can join. Specialty clinics that receive certain federal grants, such as those treating HIV or hemophilia, can also qualify.
Eligibility belongs to the organization, not to the patient. You never apply or enroll; the clinic or hospital does the signing up with HRSA. A hospital system can have some sites registered and others not, so one building under a hospital’s name may take part while a nearby office does not.
To find out whether your provider participates, ask the billing or pharmacy office directly. Notices or sliding-scale fee signs often mention 340B. HRSA also keeps a public database of participating providers.
How the 340B Discount Is Calculated
The most a drugmaker may charge is set by a formula.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments It starts from the drug’s average manufacturer price and subtracts the Medicaid rebate amount.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments For brand drugs, that means the cut is at least 23.1% of the average price, or more if the drug has been sold cheaper elsewhere.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments Drugmakers report these figures to Medicare and Medicaid officials every quarter.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments
That 23.1% is a floor, not the typical discount. The formula adds an extra rebate when a brand drug’s price climbs faster than general inflation. Older drugs with steady price hikes can therefore carry much deeper discounts. When that add-on gets large enough, the maximum 340B price can fall to a penny per unit, and the formula doesn’t let it go lower. Generic drugs use a different, smaller rebate formula, so the brand-drug figure doesn’t describe them.
The provider pays the discounted price, while insurers often still pay the provider a normal rate. The gap between what the drug cost and what was paid for it is the provider’s savings.
How 340B Works Day to Day
Discounted drugs may only go to eligible patients.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments There is no income or insurance test for patients. Instead, a patient qualifies by having an established relationship with the provider and being treated by its own staff.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments The care must also match the services the provider is funded to deliver.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments A hospital inpatient doesn’t count, since the program covers outpatient drugs.
Providers can fill 340B prescriptions in-house or through outside contract pharmacies, meaning retail pharmacies that have agreed to dispense for the provider.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments Pharmacies may keep separate shelves for 340B stock or track it by computer.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments
With an insured patient, the process looks ordinary from the counter. You hand over a prescription, the pharmacy fills it as it would any other, and your insurer is billed its usual rate. Software checks afterward whether that fill met the rules, such as being written by the provider’s own clinician, and counts it toward 340B. The pharmacy then buys replacement stock at the discounted price, so the savings arrive after you’ve already left. Your copay normally stays the same unless the provider has chosen to lower it with a separate program.
340B isn’t insurance; it’s a purchasing deal between drugmakers and providers. Some clinics do fund discount programs with the savings, and patients can ask about them.
Does 340B Lower What Patients Pay
Sometimes, when a provider passes the savings on. In one clinic’s assistance program for COPD patients, out-of-pocket drug costs dropped by about $1,550 per patient per year.6PubMed Central. Evaluation of 340B prescription assistance program on healthcare use in chronic obstructive pulmonary disease Those patients also had fewer hospital stays and ER visits, falling from about 2.4 to 1.7 a year.6PubMed Central. Evaluation of 340B prescription assistance program on healthcare use in chronic obstructive pulmonary disease Providers report using savings for free or low-cost medicines and for clinics treating diabetes, cancer and stroke.7PubMed Central. Outcomes of the 340B Drug Pricing Program
The broader evidence is mixed. Hospitals that joined did not increase unpaid care for patients overall.8PubMed Central. The 340B Drug Pricing Program and Hospital Provision of Uncompensated Care Newly joining hospitals did raise charity care about 29%, roughly $880,000 each, but they cut other community programs by about the same amount.9PubMed Central. Relationship between initiation of 340B participation and hospital safety-net engagement Discounted-care income limits also rose from about 294% to 313% of the poverty line.9PubMed Central. Relationship between initiation of 340B participation and hospital safety-net engagement
The word “340B” may not mean much to front-desk staff, so ask whether the clinic has a sliding-fee scale or a medication assistance program. Bring proof of income, such as recent pay stubs or a tax return, because many programs set eligibility by household income. Ask whether your prescription can be filled at the clinic’s own pharmacy or a partner pharmacy, since that may be where the discount applies. Uninsured patients and those with high deductibles tend to gain the most, because they would otherwise pay the full price themselves.
The Rules Against Misuse
The first main rule is that discounted drugs can’t go to ineligible patients.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments A common case is a prescription written by a doctor who isn’t employed by or contracted with the provider, so the patient lacks the required relationship. Another is a discounted drug given to a hospital inpatient. Mix-ups between 340B and regular inventory can also send discounted stock to patients who don’t qualify. Many audit findings stem from record-keeping and tracking problems, not only deliberate wrongdoing.
The second main rule is that a provider can’t let a drug get both a 340B price and a Medicaid rebate.10U.S. Government Accountability Office. 340B Drug Discount Program: Agency Oversight Has Improved, But Actions Needed To Address Weaknesses Medicaid already collects a rebate from drugmakers on drugs it pays for, so a 340B discount on the same drug would make the manufacturer pay twice. State Medicaid programs need to know which fills were 340B to leave them out of rebate claims.11U.S. Government Accountability Office. 340B Drug Discount Program: Oversight of The Intersection With The Medicaid Drug Rebate Program Needs Improvement Providers flag those prescriptions, and errors in that flagging are a main way double discounts happen.
HRSA audits providers for eligibility, diversion and duplicate discounts.12Health Resources & Services Administration. 340B Patient Definition Compliance Resources It now audits about 200 providers a year.10U.S. Government Accountability Office. 340B Drug Discount Program: Agency Oversight Has Improved, But Actions Needed To Address Weaknesses Across 1,242 audits from 2012 to 2020, it reported 546 diversion findings.2USC Schaeffer. The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments Government auditors say, however, that the audits don’t confirm problems get fixed or that only eligible hospitals take part.10U.S. Government Accountability Office. 340B Drug Discount Program: Agency Oversight Has Improved, But Actions Needed To Address Weaknesses
Why 340B Is Controversial
Much of the concern centers on specialty drugs. Five areas, including cancer, immune, antiviral and diabetes drugs, make up over two-thirds of 340B sales.13IQVIA Market Access Technology Solutions. The Size and Growth of the 340B Program in 2025 Specialty products make up about 80% of 340B sales at list price.14PubMed Central. What is driving 340B growth: utilization or price? These are costly medicines, so a percentage discount on them means a large dollar savings. Critics argue this gives providers a financial reason to prescribe or administer higher-priced drugs, though the evidence on that motive is debated.
Location is another worry. Outside sites of 340B hospitals sit in areas with median incomes over 28% higher than the parent hospital’s.15PubMed Central. Income, health, and racial gaps between 340B hospitals, child sites, and nearby neighborhoods Those areas also have lower uninsured rates.15PubMed Central. Income, health, and racial gaps between 340B hospitals, child sites, and nearby neighborhoods The original idea was to help providers serving poor and uninsured patients, so critics see this as eligibility stretching beyond its purpose. Supporters answer that those sites bring in revenue that supports the hospital’s safety-net work.
Cancer care shows a third effect. Eligible hospitals employed about 230% more cancer specialists than expected.16PubMed Central. Consequences of the 340B Drug Pricing Program Independent cancer practices face pressure as hospitals buy them up.17OncLive. Hospitals Snap Up Practices Under 340B Drug Program Once a hospital owns a practice, drugs given there can become eligible for 340B pricing, which raises the hospital’s savings. The independent practice can’t get those prices, which makes staying independent harder. For patients, a buyout can change where they go for treatment and sometimes what the visit is billed as. Because providers aren’t required to report how they use the money, the dispute is hard to settle.
The Fight Over Contract Pharmacies
Some drugmakers stopped offering 340B prices at contract pharmacies, and HHS told them they were overcharging.18RWC-340B. Update on 340B Contract Pharmacy Litigation — Decisions Issued in Four Manufacturer Lawsuits In 2021 one federal court sided with the government and another with the drugmakers.18RWC-340B. Update on 340B Contract Pharmacy Litigation — Decisions Issued in Four Manufacturer Lawsuits Many states now bar drugmakers from limiting discounts based on which pharmacy dispenses,19Frier Levitt. Navigating 340B Price Discrimination: How State Laws Protect Covered Entities and Contract Pharmacies and 21 states have passed contract-pharmacy-specific laws.20National Association of Community Health Centers. What Is the 340B Drug Pricing Program: How It Works
The disagreement is about what the law requires. Drugmakers argue it requires discounts only for the provider’s own pharmacy, not any number of outside pharmacies the provider picks. The government and providers say the law requires sales at the ceiling price to covered entities and doesn’t limit where drugs are dispensed. The number of outside pharmacies providers use has grown over time, which is part of why drugmakers pushed back. Their restrictions often limit how many pharmacies they will ship to or require claims data. Clinics without their own pharmacy rely on outside ones, so restrictions can shrink their savings. Because courts reached opposite results, what a provider can do depends partly on where it is located and which court’s ruling applies.
340B in Rural Hospitals
There is some evidence rural Critical Access Hospitals passed 340B savings on to patients.21PubMed. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B These hospitals, however, can’t get 340B prices on rare-disease drugs.22INNOVATIONS in pharmacy. Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals Those drugs treat rare conditions and are often among the most expensive medicines, so leaving them out removes a large source of potential savings. In one group of 18 such hospitals, those drugs were 44% of drug spending but only 5% of units.22INNOVATIONS in pharmacy. Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals The hospitals missed about $171,000 in savings per hospital each year,22INNOVATIONS in pharmacy. Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals a significant sum for a facility with a small budget. Small rural hospitals often run on thin margins, so savings can help keep a local pharmacy or infusion service open.

